Seegnal lists on Frankfurt Stock Exchange
Analysis based on 6 articles · First reported Jul 10, 2026 · Last updated Jul 10, 2026
The dual listing on the Frankfurt Stock Exchange may increase Seegnal's visibility and attract European investors, potentially improving liquidity and share price. However, the impact is likely modest given the company's small size and early stage.
Seegnal Inc., a developer of healthcare technology focused on mitigating medication risks, announced that its common shares commenced trading on the Frankfurt Stock Exchange (FSE) on July 10, 2026, under the ticker symbol '2I1' (WKN: A41FV7). The company's shares continue to trade on the TSX Venture Exchange under the symbol 'SEGN'. The listing on the FSE, operated by Deutsche Bank AG, is expected to increase Seegnal's visibility and accessibility among European and international investors. Seegnal's SaaS-based clinical decision support platform is used by approximately 15,000 clinicians in daily practice.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard